ASKA Pharmaceutical Holdings Co Ltd
TSE:4886

Watchlist Manager
ASKA Pharmaceutical Holdings Co Ltd Logo
ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
Watchlist
Price: 2 306 JPY 2.04% Market Closed
Updated: May 24, 2024

ASKA Pharmaceutical Holdings Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ASKA Pharmaceutical Holdings Co Ltd
Income from Continuing Operations Peer Comparison

Comparables:
4502
4568
4578
4519
4503

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
ASKA Pharmaceutical Holdings Co Ltd
TSE:4886
Income from Continuing Operations
¥7.5B
CAGR 3-Years
41%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Income from Continuing Operations
¥144.2B
CAGR 3-Years
-27%
CAGR 5-Years
1%
CAGR 10-Years
3%
Daiichi Sankyo Co Ltd
TSE:4568
Income from Continuing Operations
¥201B
CAGR 3-Years
39%
CAGR 5-Years
16%
CAGR 10-Years
12%
Otsuka Holdings Co Ltd
TSE:4578
Income from Continuing Operations
¥141.7B
CAGR 3-Years
-4%
CAGR 5-Years
11%
CAGR 10-Years
-1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Income from Continuing Operations
¥326.4B
CAGR 3-Years
16%
CAGR 5-Years
27%
CAGR 10-Years
18%
Astellas Pharma Inc
TSE:4503
Income from Continuing Operations
¥17B
CAGR 3-Years
-48%
CAGR 5-Years
-40%
CAGR 10-Years
-15%

See Also

What is ASKA Pharmaceutical Holdings Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
7.5B JPY

Based on the financial report for Mar 31, 2024, ASKA Pharmaceutical Holdings Co Ltd's Income from Continuing Operations amounts to 7.5B JPY.

What is ASKA Pharmaceutical Holdings Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
34%

Over the last year, the Income from Continuing Operations growth was 78%. The average annual Income from Continuing Operations growth rates for ASKA Pharmaceutical Holdings Co Ltd have been 41% over the past three years , 34% over the past five years .